Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesReversibility of capillary density after discontinuation of bevacizumab treatment
Annals of Oncology, 10/29/09
Steeghs N et al. – Bevacizumab–induced decrease in capillary density is reversible. Noninvasive assessment of capillary density during treatment with antiangiogenic drugs may be useful as a marker of treatment efficacy.
Related Articles
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
Journal of Clinical Oncology, 11/19/09
Relevance Score: 92%
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
British Journal of Cancer, 11/20/09
Relevance Score: 91%
Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies
Journal of Cancer Research & Clinical Oncology, 11/17/09
Relevance Score: 91%
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 91%
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
Journal of Clinical Oncology, 10/22/09
Relevance Score: 89%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting
Internal Medicine Journal, 03/19/10
Anticancer effects of CAMEL peptide
Laboratory Investigation, 03/19/10
High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
British Journal of Haematology, 03/19/10
Sponsor
Article Search
Sponsor
Sponsor